Home > Riviste > Minerva Anestesiologica > Fascicoli precedenti > Minerva Anestesiologica 2013 February;79(2) > Minerva Anestesiologica 2013 February;79(2):185-93

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

REVIEWS   Freefree

Minerva Anestesiologica 2013 February;79(2):185-93

Copyright © 2013 EDIZIONI MINERVA MEDICA

lingua: Inglese

Rituximab in critically ill patients

Dimopoulos G. 1, Armaganidis A. 1, Poulakou G. 2, Matthaiou D. K. 2

1 Department of Critical Care, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece; 2 .4th Department of Internal Medicine, Medical School, University of Athens, “Attikon” University Hospital, Athens, Greece


PDF


Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.

inizio pagina